Abstract:Lung cancer is the leading cause of cancer-related mortality worldwide. Despite progress in the treatment of non-small-cell lung cancer, there are limited treatment options for lung squamous cell carcinoma (LUSC), compared with lung adenocarcinoma. The present study investigated the disease mechanism of LUSC in order to identify key candidate genes for diagnosis and therapy. A total of three gene expression profiles (GSE19188, GSE21933 and GSE74706) were analyzed using GEO2R to identify common differentially expressed genes (DEGs). The DEGs were then investigated using Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis. A protein-protein interaction (PPI) network was constructed via the Search Tool for the Retrieval of Interacting Genes/Proteins, and visualized using Cytoscape software. The expression levels of the hub genes identified using CytoHubba were validated using the University of California, Santa Cruz (UCSC) database and the Human Protein Atlas. A Kaplan-Meier curve and Gene Expression Profiling Interactive Analysis were then employed to evaluate the associated prognosis and clinical pathological stage of the hub genes. Furthermore, non-coding RNA regulatory networks were constructed using the Gene-Cloud Biotechnology information website. A total of 359 common DEGs (155 upregulated and 204 downregulated) were identified, which were predominantly enriched in ‘mitotic nuclear division’, ‘cell division’, ‘cell cycle’ and ‘p53 signaling pathway’. The PPI network consisted of 257 nodes and 2,772 edges, and the most significant module consisted of 66 upregulated genes. A total of 19 hub genes exhibited elevated RNA levels, and 10 hub genes had elevated protein levels compared with normal lung tissues. The upregulation of five hub genes (CCNB1, CEP55, FOXM1, MKI67 and TYMS; defined in Table I) were significantly associated with poor overall survival and unfavorable clinical pathological stages. Various ncRNAs, such as C1orf220, LINC01561 and MGC39584, may also play important roles in hub-gene regulation. In conclusion, the present study provides further understanding of the pathogenesis of LUSC, and reveals CCNB1, CEP55, FOXM1, MKI67 and TYMS as potential biomarkers or therapeutic targets.

Identification and Integrated Analysis of Key Biomarkers for Diagnosis and Prognosis of Non-Small Cell Lung Cancer

Identification of Key Genes and Evaluation of Clinical Outcomes in Lung Squamous Cell Carcinoma Using Integrated Bioinformatics Analysis

Identification of Candidate Biomarkers Correlated With the Pathogenesis and Prognosis of Non-small Cell Lung Cancer via Integrated Bioinformatics Analysis

Prognostic Biomarkers after Radiotherapy for Nonsmall Cell Lung Cancer Based on Bioinformatics Analysis

Identification and Integrate Analysis of Key Biomarkers for Diagnosis and Prognosis of Non-Small Cell Lung Cancer Based on Bioinformatics Analysis

An integrated bioinformatics approach to early diagnosis, prognosis and therapeutics of non-small-cell lung cancer

Identification and validation of differentially expressed genes for targeted therapy in NSCLC using integrated bioinformatics analysis

Identification and validation of key genes with prognostic value in non‐small‐cell lung cancer via integrated bioinformatics analysis

Identification of Key Genes in Non-Small Cell Lung Cancer by Bioinformatics Analysis

Identification Of Novel Biomarkers And Candidate Small Molecule Drugs In Non-Small-Cell Lung Cancer By Integrated Microarray Analysis

Survival-based Bioinformatics Analysis to Identify Hub Genes and Key Pathways in Non-Small Cell Lung Cancer

Identification and verification of hub genes associated with the progression of non-small cell lung cancer by integrated analysis

Identification of Key Biomarkers and Candidate Molecules in Non-Small-Cell Lung Cancer by Integrated Bioinformatics Analysis

Single-cell RNA-seq Analysis to Identify Potential Biomarkers for Diagnosis, and Prognosis of Non-Small Cell Lung Cancer by Using Comprehensive Bioinformatics Approaches.

Target gene screening and evaluation of prognostic values in non-small cell lung cancers by bioinformatics analysis.

Bioinformatics Analysis Reveals 6 Key Biomarkers Associated with Non-Small-cell Lung Cancer

Identification of genes and pathways leading to poor prognosis of non-small cell lung cancer using integrated bioinformatics analysis

Identification of Key Differentially Expressed Genes Associated with Non‑small Cell Lung Cancer by Bioinformatics Analyses.

Identification of Genes and Analysis of Prognostic Values in Nonsmoking Females with Non-Small Cell Lung Carcinoma by Bioinformatics Analyses

Identification of Prognostic Markers by Weighted Gene Co‐expression Network Analysis in Non-Small Cell Lung Cancer

A gene expression signature predicts survival of patients with stage I non-small cell lung cancer.